Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

Journal of Infectious Diseases

Volumn 194, Issue 7, 2006, Pages 926-930

  Hunt, Peter W ^a,g   Harrigan, P Richard ^f   Huang, Wei ^e   Bates, Michael ^e   Williamson, David W ^a,d   McCune, Joseph W ^a   Price, Richard W ^b   Spudich, Serena S ^b   Lampiris, Harry ^a   Hoh, Rebecca ^a   Leigler, Teri ^a   Martin, Jeffrey N ^a,b,c   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e MONOGRAM BIOSCIENCES   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RECEPTOR;

ADULT; ARTICLE; CCR5 GENE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; VIREMIA; VIRUS RECOMBINANT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 33749039498     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507312     Document Type: Article

References (15)

1. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354-60.
2. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of anti-retroviral-naive individuals. J Infect Dis 2005; 192:466-74.
3. Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004; 189:312-21.
4. Harouse JM, Buckner C, Gettie A, et al. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci USA 2003; 100:10977-82.
5. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-9.
6. Giovannetti A, Ensoli F, Mazzetta F, et al. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin Exp Immunol 1999; 118:87-94.
7. Yuan W, Craig S, Si Z, Farzan M, Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004; 78:5448-57.
8. Boucher CA, Lange JM, Miedema FF, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992; 6:1259-64.
9. Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191:890-8.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-24.
11. Elbeik T, Alvord WG, Trichavaroj R, et al. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr 2002; 29:330-9.
12. Demarest JF, Bonny T, Vavro CL. HIV-1 co-receptor tropism in treatment naive and experienced subjects [abstract H-1136]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Herndon, VA: ASM Press, 2004:300.
13. Wilkin T, Su Z, Kuritzkes D, et al. Co-receptor tropism in patients screening for ACTG 5211, a phase 2 study of Vicriviroc, a CCR5 inhibitor [abstract 655], In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006:283.
14. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003; 77:7682-8.
15. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-17.